European Union - Maltese - EMA (European Medicines Agency)

intervet international bv - fenbendazole - anthelmintics, , il-benżimidażoli u sustanzi relatati, fenbendażol - pigs; chicken - għat-trattament u l-kontroll tal-ħniex gastro-intestinali fil-ħnieżer infettati bil -: ascaris suum (adulti, intestinali u l-migrazzjoni-istadji tal-larva);oesophagostomum spp. (adulti istadji);trichuris suis (adulti istadji). għat-trattament tal-ħniex gastro-intestinali fit-tiġieġ infettati bil -: ascaridia galli (l5 u l-adulti l-istadji);heterakis gallinarum (l5 u l-adulti l-istadji);capillaria spp. (l5 u l-adulti l-istadji).

European Union - Maltese - EMA (European Medicines Agency)

horizon therapeutics ireland dac - inebilizumab - neuromyelitis optica - immunosoppressanti - uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (nmosd) who are anti-aquaporin 4 immunoglobulin g (aqp4-igg) seropositive (see section 5.

European Union - Maltese - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - emoglobinurja, paroxysmal - immunosuppressanti selettivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

European Union - Maltese - EMA (European Medicines Agency)

roche registration gmbh - satralizumab - neuromyelitis optica - immunosoppressanti - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

European Union - Maltese - EMA (European Medicines Agency)

alexion europe sas - eculizumab - emoglobinurja, paroxysmal - immunosoppressanti - soliris huwa indikat fl-adulti u t-tfal għall-kura ta': emoglobinurja notturnali parossimali (pnh). l-evidenza ta 'benefiċċju kliniku hija murija f'pazjenti b'emodijalisi ma' sintomi kliniċi(i) indikattiv ta'l-attività għolja tal-marda, irrispettivament mill-trasfużjoni-istorja (ara sezzjoni 5. atipiċi sindromu uremiku emolitiku (ahus). soliris huwa indikat fl-adulti għall-kura ta': ġeneralizzati refrattarji myasthenia gravis (gmg) f'pazjenti li huma kontra l-acetylcholine-riċettur (achr) antikorpi pożittivi (ara sezzjoni 5. neuromyelitis maws ottiku għall-logħob tal-ispettru disturb (nmosd) f'pazjenti li huma kontra l-aquaporin-4 (aqp4) antikorpi pożittivi bl-isklerożi multipla reċidiva-kors tal-marda.

European Union - Maltese - EMA (European Medicines Agency)

zoetis belgium sa - klieb distemper virus, razza cdv bio 11/a, klieb adenovirus tat-tip 2, razza cav-2 bio 13, klieb parvovirus tip 2b, razza cpv-2b bio 12/b u l-klieb parainfluenza tat-tip 2 virus, razza cpiv-2 bio 15 (kollha ħaj attenwat) - immunoloġiċi għall-canidae, vaċċini virali Ħajjin - klieb - immunizzazzjoni attiva ta 'klieb minn sitt ġimgħat. biex tipprevjeni l-mortalità u sinjali kliniċi ikkawżati mill-klieb distemper virus,biex jimpedixxi l-mortalità u sinjali kliniċi ikkawżati mill-klieb adenovirus tat-tip 1,li jipprevjenu l-sinjali kliniċi u l-eskrezzjoni virali kkawżata mill-klieb adenovirus tat-tip 2,għall-prevenzjoni ta ' sinjali kliniċi, lewkopenija u l-eskrezzjoni virali kkawżata mill-klieb parvovirus,għall-prevenzjoni tal-sinjali kliniċi u l-eskrezzjoni virali kkawżata mill-klieb parainfluenza virus.

European Union - Maltese - EMA (European Medicines Agency)

amivas ireland ltd - artesunate - malarja - antiprotozoali - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu adattat ta ' aġenti antimalarial.

European Union - Maltese - EMA (European Medicines Agency)

zoetis belgium sa - virus tal-parainfluenza tal-kannamiela tat-tip 2, ir-razza cpiv-2 bio 15 (ħaj attenwat) - immunoloġiċi għall-canidae, vaċċini virali Ħajjin - klieb - tilqim attiv ta 'klieb ta' sitt ġimgħat għall-prevenzjoni tal-sinjali kliniċi (nażali u okulari kwittanza) u l-eskrezzjoni virali kkawżata mill-klieb parainfluenza virus.

European Union - Maltese - EMA (European Medicines Agency)

elanco gmbh - monensin (bħala monensin sodium) - mediċini għall-prevenzjoni u/jew it-trattament tal-acetonemia - baqar (baqar u erħiet) - għat-tnaqqis fl-inċidenza ta 'ketożi fil-baqra tal-ħalib peri-parturient / għoġġiela li hija mistennija li tiżviluppa ketożi.

European Union - Maltese - EMA (European Medicines Agency)

mylan pharmaceuticals limited - atazanavir (as sulfate) - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - atazanavir mylan, mogħti flimkien ma 'doża baxxa ta' ritonavir, huwa indikat għall-kura ta 'adulti infettati bl-hiv 1 u pazjenti pedjatriċi ta' 6 snin jew aktar flimkien ma 'prodotti mediċinali antiretrovirali oħra. ibbażat fuq disponibbli viroloġiku u kliniku minn pazjenti adulti, m'hu mistenni ebda benefiċċju f'pazjenti b'razez reżistenti għall-inibituri ta'proteasi multipliċi (≥ 4 mutazzjonijet pi). hemm tagħrif limitat ħafna disponibbli minn tfal ta '6 snin għal inqas minn 18-il sena. l-għażla ta ' atazanavir mylan fl-esperjenza ta'trattament għall-adulti u f'pazjenti pedjatriċi għandu jkun ibbażat fuq testijiet tar-reżistenza virali u l-istorja tat-trattament tal-pazjent.